Relations Between Atherogenic Index of Plasma, Ratio of Small Dense Low Density Lipoprotein/Lecithin Cholesterol Acyl Transferase and Ratio of Small Dense Low Density Lipoprotein/Cholesteryl Ester Transfer Protein of Controlled and Uncontrolled Type 2 DM

Ellis Susanti, Marsetio Donosepoetro, Gatot Susilo Lawrence


BACKGROUND: Patients with Diabetes Melitus are proven to be prone to atherosclerosis and coronary heart disease, especially type 2 Diabetes Melitus (T2DM) patient who have higher risk and mortality for cardiovascular risk factor. The Dyslipidemia condition is very common in T2DM as one of the risk factors. Diabetic dyslipidemia is marked by the increased triglyceride (TG), low HDL cholesterol (HDL-C), and increased small dense LDL and apolipoprotein B. Therefore the aim of this study is to assess the differential and correlation between Atherogenic Index of Plasma (AIP), ratio of small dense low density lipoprotein (sdLDL)/lecithin cholesterol acyl transferase (LCAT) and ratio of sdLDL/cholesteryl ester transfer protein (CETP) of controlled and uncontrolled T2DM.

METHODS: This study was observational with cross sectional design. In total of 72 patients with T2DM consist of 36 controlled and 36 uncontrolled, participated in this study. The serum TG, HDL-C, sdLDL, LCAT and CETP were examined in their relationship with to T2DM risk.

RESULTS: The results of the study indicate that the AIP (p<0.001) increase controlled and uncontrolled T2DM and the ratio of sdLDL/CETP (p=0.004), odds ratio of AIP was 4 (95% CI : 1.501-10.658) and odds ratio of sdLDL/CETP ratio was 4 (95% CI : 1.501-10.658) in uncontrolled T2DM.

CONCLUSION: This study showed that the AIP and ratio of small dense LDL/CETP had a significant correlation with the uncontrolled T2DM. The AIP and ratio of small dense LDL/CETP increase was found at the uncontrolled T2DM to be 4 times greater than the controlled T2DM.

KEYWORDS: T2DM, atherosclerosis, atherogenic index of plasma, small dense LDL, LCAT, CETP, ratio of sdLDL/LCAT, ratio of sdLDL/CETP

Full Text:



Selvin E, Coresh J, Golden SH, Boland LL, Brancati FL, Steffes MW. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diab Care. 2005; 28: 1965-73, CrossRef.

Dobiasova M, Jiri Frohlich. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and estherification rate inapob-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001; 34: 583-58, CrossRef.

Maassen JA, Hart LM, van Essen E, Heine RJ, Nijpels G, Tafrechi RSJ, et al. Molecular mechanism and clinical presentation. Diabetes. 2004; 53 (Suppl 1): S103-S109, CrossRef.

Bays H. Atherogenic dyslipidemia in type 2 diabetes and metabolic syndrome: current and future treatment options. Br J Diabetes Vasc Dis. 2003; 3: 356-60, CrossRef.

Santamarina-Fojo S, Lambert G, Hoeg JM, Brewer HB. Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol. 2000; 11: 267-75, CrossRef.

Bell DSH. Diabetes mellitus and coronary artery disease. J Cardiovasc Risk. 1997; 4: 83-90, CrossRef.

Libby P. Managing the risk of atherosclerosis: the role of high density lipoprotein. Am J Cardiol. 2001; 88: 3N-8N, CrossRef.

Betteridge DJ. LIPIDS: Current perspectives. London: Martin Dunitz Ltd; 1996, NLMID.

Bell DSH. Diabetes mellitus and coronary artery disease. J Cardiovasc Risk. 1997; 4: 83-90, CrossRef.

Tkac I, Kimball BP, Lewis G, Uffelman K, Steiner G. The severity coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Artherioscler Thromb Vasc Biol. 1997; 17: 3633-8, CrossRef.

Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004; 50: 1184-8, CrossRef.

Miller YL, Chang MK, Binder CJ, Shaw PX, Witztum JL. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol. 2003; 14: 437-45, CrossRef.

Rifai N, Warnick GR, Dominiczak MH. Handbook of lipoprotein testing. Washington: AACC Inc; 1997, NLMID.

Fenske D. Lipid transport. Canada: Course Material The University of British Columbia; 2005.

Lewis GF, Rader GJ. New insight into regulation of HDL metabolism and reverse cholesterol transport. Circulation Research. 2005; 96: 1221-32, CrossRef.

Klerkx AHEM, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ESG, Kastelein JJP, et al. Cholesterol ester transfer protein (CETP) inhibition beyond raising high density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol. 2006; 26: 706-15, CrossRef.

Forrester JS, Makkar R, Shah PK. Increasing high density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition. Circulation. 2005; 111: 1847-54, CrossRef.


Indexed by:






The Prodia Education and Research Institute